Encompass Health Corp’s recently made public that its Chief Medical Officer Charbonneau Elissa Joy unloaded Company’s shares for reported $0.5 million on May 06 ’25. In the deal valued at $116.61 per share,4,279 shares were sold. As a result of this transaction, Charbonneau Elissa Joy now holds 11,958 shares worth roughly $1.45 million.
Then, Darby John Patrick sold 10,000 shares, generating $1,147,900 in total proceeds. Upon selling the shares at $114.79, the EVP, Gen Counsel & Secretary now owns 79,710 shares.
Before that, COLTHARP DOUGLAS E sold 43,575 shares. Encompass Health Corp shares valued at $5,017,538 were divested by the EVP & Chief Financial Officer at a price of $115.15 per share. As a result of the transaction, COLTHARP DOUGLAS E now holds 60,335 shares, worth roughly $7.29 million.
KeyBanc Capital Markets initiated its Encompass Health Corp [EHC] rating to an Overweight in a research note published on October 11, 2024; the price target was $115. A number of analysts have revised their coverage, including Leerink Partners’s analysts, who began to cover the stock in early July with a ‘”an Outperform”‘ rating. Barclays began covering EHC with “an Overweight” recommendation on March 06, 2024. Barclays started covering the stock on March 14, 2023. It rated EHC as “an Equal weight”.
Price Performance Review of EHC
On Friday, Encompass Health Corp [NYSE:EHC] saw its stock jump 0.92% to $120.87. Over the last five days, the stock has gained 3.83%. Encompass Health Corp shares have risen nearly 30.88% since the year began. Nevertheless, the stocks have risen 39.17% over the past one year. While a 52-week high of $119.95 was reached on 05/16/25, a 52-week low of $82.74 was recorded on 01/03/25. SMA at 50 days reached $105.22, while 200 days put it at $98.27.
Levels Of Support And Resistance For EHC Stock
The 24-hour chart illustrates a support level at 118.99, which if violated will result in even more drops to 117.11. On the upside, there is a resistance level at 122.01. A further resistance level may holdings at 123.16. The Relative Strength Index (RSI) on the 14-day chart is 74.13, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 2.61, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 5.60%. Stochastics %K at 95.28% indicates the stock is a selling.
The most recent change occurred on September 24, 2021 when UBS began covering the stock and recommended ‘”a Buy”‘ rating along with a $98 price target.
